Thu Oct 23 13:07:38 SGT 2014  
STD
TESTING
SINGAPORE™
    HIV Window Period
STD TESTING SINGAPORE™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

HIV Window Period | STD TESTING SINGAPORE™

Summary

HIV Window Period | STD TESTING SINGAPORE™ @stdtestingsingapore_com: HIV (human immunodeficiency virus) window period, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
STD TESTING SINGAPORE™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: HIV Window Period | STD TESTING SINGAPORE™
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

HIV window period is the time from HIV infection until a HIV Test can detect any change. Within the HIV window period, the HIV Test would be negative. During this period, the HIV viral load is extremely high, thus making the person highly infectious.
  • 4 weeks after exposure, a negative 4th generation HIV ELISA Test "is very reassuring / highly likely to exclude HIV infection."
  • 12 weeks after exposure, a negative 3rd generation HIV ELISA Test "would definitively exclude HIV infection."
References HIV is the abbreviation for the human immunodeficiency virus, which causes the acquired immunodeficiency syndrome

HIV symptoms which may present in acute HIV infection:

These are nonspecific symptoms and can present with other infections; consequently, they are unreliable indicators of HIV infection.

Kaposi's sarcoma Remember, there is no HIV cure.

HIV Test

Window
period
Test
Notes Sampling Method
Time to Results
Cost / Price
0-72 hours
No test available
2 weeks (as short as 10-12 days)
HIV DNA test
  • A PCR (polymerase chain reaction) NAT (nucleic acid test) for HIV-1 proviral DNA, therefore a HIV DNA Test.
  • Method: Proviral DNA Polymerase Chain Reaction (Roche Amplicor HIV-1 DNA Test, V1.5) This test uses primers SK145 and SKCC1B to define a sequence of 155 nucleotides within a highly conserved region of the HIV-1 gag gene.
  • Usually used for the early diagnosis of HIV infection in neonates born to HIV+ mothers. As maternal antibodies circulate in the child for several months, the HIV antibody test would be positive.
  • Also used for early HIV diagnosis in adults.
Venipuncture
(Monday-Friday
before 10am)
1-2 weeks
SG$876/=
1 month
HIV combo test
Fingerprick
20 minute
HIV rapid test
SG$150/=
1 month
HIV duo test
Venipuncture

1-2 days
SG$48/=
3 months
OraQuick®
HIV oral test /
HIV saliva test /
Fingerprick
20 minute
HIV rapid test
SG$50/=
3 months
HIV blood test
Venipuncture
1-2 days
SG$12/=
HIV
confirmation
HIV western blot test
Venipuncture
1-2 weeks
SG$275/=
HIV
follow-up
HIV RNA test
Venipuncture
(Monday-Friday
before 10am)
1-2 weeks
SG$717/=

HIV ELISA (Enzyme-linked immunosorbent assay) test generations:

  1. 1st generation: HIV-1 IgG antibody
  2. 2nd generation: HIV-1 & HIV-2 IgG antibodies
  3. 3rd generation: HIV-1 & HIV-2 IgG & IgM antibodies
  4. 4th generation: HIV-1 & HIV-2 IgG & IgM antibodies and HIV p24 antigen
References HIV rapid test (20 minutes to results) Two types are available:

Note: If the clinic attendance is only for the HIV rapid test, then consultation fees are not added.

References

HIV PCR (polymerase chain reaction) NAT (nucleic acid test) HIV Risk (2009 figures)

Estimated HIV transmission risk per exposure for specific activities and events
Activity Risk-per-exposure
Vaginal sex, female-to-male, studies in high-income countries 0.04% (1:2380)
Vaginal sex, male-to-female, studies in high-income countries 0.08% (1:1234)
Vaginal sex, female-to-male, studies in low-income countries 0.38% (1:263)
Vaginal sex, male-to-female, studies in low-income countries 0.30% (1:333)
Vaginal sex, source partner is asymptomatic 0.07% (1:1428)
Vaginal sex, source partner has late-stage disease 0.55% (1:180)
Receptive anal sex amongst gay men, partner unknown status 0.27% (1:370)
Receptive anal sex amongst gay men, partner HIV positive 0.82% (1:123)
Receptive anal sex with condom, gay men, partner unknown status 0.18% (1:555)
Insertive anal sex, gay men, partner unknown status 0.06% (1:1666)
Insertive anal sex with condom, gay men, partner unknown status 0.04% (1:2500)
Receptive fellatio Estimates range from 0.00% to 0.04% (1:2500)
Mother-to-child, mother takes at least two weeks antiretroviral therapy 0.8% (1:125)
Mother-to-child, mother takes combination therapy, viral load below 50 0.1% (1:1000)
Injecting drug use Estimates range from 0.63% (1:158) to 2.4% (1:41)
Needlestick injury, no other risk factors 0.13% (1:769)
Blood transfusion with contaminated blood 92.5% (9:10)
Sources: vaginal sex;1 anal sex;2 fellatio;3 2 mother-to-child;4 other activities.5

References

  1. Boily MC et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9(2): 118-129, 2009
  2. Vittinghoff E et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. American Journal of Epidemiology 150: 306-311, 1999
  3. Del Romero J et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS 16(9): 1296-1297, 2002
  4. Townsend C et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22: 973-981, 2008
  5. Baggaley RF et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion. AIDS 20: 805-812, 2006
  6. HIV & AIDS Information :: How transmission occurs - Estimated risk per exposure
HIV Risk (2005 figures)

Estimated per-act risk for acquisition of HIV, by exposure route*

Exposure routeRisk per 10,000
exposures
to an infected source
%
Blood transfusion900090
Needle-sharing injection-drug use670.67
Receptive anal intercourse500.5
Percutaneous needle stick300.3
Receptive penile-vaginal intercourse100.1
Insertive anal intercourse6.50.065
Insertive penile-vaginal intercourse50.05
Receptive oral intercourse†10.01
Insertive oral intercourse†0.50.005
*Estimates of risk for transmission from sexual exposures assume no condom use.
†Source refers to oral intercourse performed on a man.

References

HIV risk (2002 figures)

HIV Risk Statistics (chances of getting HIV)
HIV Risk Factors HIV Transmission Probability
Needle stick injury3 1/300
Receptive anal intercourse4 1/100
Receptive vaginal intercourse5 1/1000
Insertive vaginal intercourse4 1/2000
Insertive anal intercourse4 1/2500
Receptive fellatio with ejaculation4 1/2500
Sharing needles6 1/150

References

  1. Cardo DM, Culver DH, Ciesielski CA, et al. A Case-Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure. N Engl J Med. 1997;337:1485-1490.
  2. Katz MH, Gerberding JL. Management of occupational and nonoccupational postexposure HIV prophylaxis. Current Inf Dis Reports. 2002;4:543-549.
  3. Gerberding JL. Prophylaxis for Occupational Exposure to HIV. Ann Intern Med. 1996;6:497-501
  4. Vitinghoff E, Douglas J, Judon F, et al. Per-Contact Risk of Human Immunodificiency Virus Transmision between Male Sexual Partners. Am J Epidemiol. 1999;150:306-311.
  5. Peterman TA, Stoneburner RL, Allen JR, et al. Risk of Human Immunodeficiency Virus Transmission From Heterosexual Adults With Transfusion-Associated Infections. JAMA. 1988;259:55-58. [Erratum. JAMA. 1989;262:502]
  6. Kaplan EH, Heimer R. A Model-Based Estimate of HIV Infectivity via Needle Sharing. J Acquir Immune Defic Syndr. 1992;5:1116-1118.
HIV prevention / HIV PEP (post-exposure prophylaxis) treatment can prevent you from getting an HIV infection, and turning HIV positive.

Individuals are eligible for HIV PEP Treatment if all the following criteria are met:

  1. less than 72 hours has elapsed since exposure;
    and
  2. the exposed individual is not known to be HIV infected;
    and
  3. the person who is the source of exposure is HIV infected or has unknown HIV status;
    and
  4. mucous membrane or non-intact skin was exposed to a potentially infectious body fluid;
Prompt antiviral therapy may reduce the risk of HIV transmission by as much as 80%.

For optimal efficacy, antiretroviral therapy should be started as soon as possible, ideally within 1 hour of exposure. So that you can remain HIV negative.

The medications and dosages are the same as those used for lifelong treatment of HIV patients. However, for HIV PEP treatment, it is taken for only a month.

Algorithm for evaluation and treatment of possible nonoccupational HIV exposures
References Drugs commonly used in HIV PEP: References TORCH

TORCH complex is a medical acronym for a set of perinatal infections (i.e. infections that are passed from a pregnant woman to her fetus), that can lead to severe fetal anomalies or even fetal loss.
Other agents are:

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Eosinophilic gastroenteritis with involvement of the urinary bladder
Wed, 22 Oct 2014 02:23:16 +0100 | Pediatric Radiology
We describe the CT findings of eosinophilic gastroenteritis accompanied by bladder involvement in an 11-year-old boy. CT imaging showed diffuse wall thickening of the entire gastrointestinal tract from the esophagus to the colon and revealed a halo sign, irregular fold thickening and luminal narrowing without obstruction of the gastrointestinal wall. Another CT finding was the diffuse thickening of the bladder wall with moderate enhancement on postcontrast CT. The boy underwent endoscopic biopsy from various sites of the gut wall and histology revealed increased eosinophiliac infiltration in the mucosa. After corticosteroid therapy, the boy recovered gradually. The case emphasizes that not only the gastrointestinal tract but also the urinary bladder may be involved in children with eosinop...

Lactoferrin levels in gingival crevicular fluid and saliva of HIV‐infected patients with chronic periodontitis
Tue, 21 Oct 2014 21:06:12 +0100 | Journal of Investigative and Clinical Dentistry
ConclusionThe data indicate that LF levels in the GCF and saliva are not different between HIV‐infected and noninfected patients with chronic periodontitis. (Source: Journal of Investigative and Clinical Dentistry)

LabCorp launches test to help guide drug treatments for HIV patients
Tue, 21 Oct 2014 15:58:00 +0100 | bizjournals.com Health Care:Hospitals headlines
Burlington-based LabCorp is launching the first test of its kind to help doctors optimize the drug regimens they rely on for treating HIV patients.

Ethiopia: Toil Here
Tue, 21 Oct 2014 09:08:49 +0100 | AllAfrica News: HIV-Aids and STDs
[Addis Fortune]One of the major aspects of Addis Abeba subject to criticism is the lack of appropriate public toilets. This seems a good start, inside Megenagna Square, where many people take taxis and some trade. The service provider is a union of HIV positive and disabled people, totalling 16 individuals in all. They give services from seven in the morning to eight thirty in the evening, charging 50 cents. These people wear a badge stamped "sew ale" in Amharic, which literally means "there is someone" - a phrase used w (Source: AllAfrica News: HIV-Aids and STDs)

Tanzania: Call for Cut of HIV/Aids Prevalence in Key Groups
Tue, 21 Oct 2014 08:47:56 +0100 | AllAfrica News: HIV-Aids and STDs
[Daily News]ALTHOUGH the nation has recorded impressive success in fighting HIV and AIDS in the country, the disease's prevalence is still high in key population groups. (Source: AllAfrica News: HIV-Aids and STDs)

Nigeria: Elimination of Mother-to-Child HIV Transmission Is Crucial to the MDGs - - Idoko
Tue, 21 Oct 2014 07:21:10 +0100 | AllAfrica News: HIV-Aids and STDs
[Vanguard]The National Agency for the Control of AIDS, NACA, has described the upcoming launch of National Plan for the country's Elimination of Mother-to-Child Transmission of HIV, eMTCT, initiative as being in line with the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. (Source: AllAfrica News: HIV-Aids and STDs)

[Newsdesk] Research brief
Tue, 21 Oct 2014 06:15:25 +0100 | The Lancet Infectious Diseases
30 years after AIDS first emerged in the USA, the geographical source and early dissemination of HIV-1 in the human population remains controversial. A new evolutionary analysis of HIV-1 sequence data from central Africa suggests that the HIV-1 group M viruses originated in Kinshasa (Democratic Republic of the Congo) in the early 1920s and then, because the city was an important commercial transportation hub, spread across central Africa. An exponential increase in group M infections after 1960 suggests that post-independence changes in sexual behaviour in and around Kinshasa might have driven the epidemic growth of the HIV-1 group M pandemic. (Source: The Lancet Infectious Diseases)

Government prosecutes alleged scientific fraud on AIDS research
Tue, 21 Oct 2014 03:39:18 +0100 | CNN.com - Health
If government prosecutors are right, a former top researcher at Iowa State University is guilty of brazen scientific fraud-actions which a criminal complaint says have cost taxpayers nearly $15 million. (Source: CNN.com - Health)

A Strategic Approach to Public Health Workforce Development and Capacity Building
Tue, 21 Oct 2014 00:00:00 +0100 | American Journal of Preventive Medicine
Publication date: November 2014 Source:American Journal of Preventive Medicine, Volume 47, Issue 5, Supplement 3 Author(s): Hazel D. Dean , Ranell L. Myles , Crystal Spears-Jones , Audriene Bishop-Cline , Kevin A. Fenton In February 2010, CDC’s National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease (STD), and Tuberculosis (TB) Prevention (NCHHSTP) formally institutionalized workforce development and capacity building (WDCB) as one of six overarching goals in its 2010–2015 Strategic Plan. Annually, workforce team members finalize an action plan that lays the foundation for programs to be implemented for NCHHSTP’s workforce that year. This paper describes selected WDCB programs implemented by NCHHSTP during the last 4 years in the three strategic goal areas: (1) ...

Meeting the Emerging Public Health Needs of Persons With Blood Disorders
Tue, 21 Oct 2014 00:00:00 +0100 | American Journal of Preventive Medicine
Publication date: November 2014 Source:American Journal of Preventive Medicine, Volume 47, Issue 5 Author(s): Christopher S. Parker , James Tsai , Azfar-e-Alam Siddiqi , Hani K. Atrash , Lisa C. Richardson In its decades-long history, the Division of Blood Disorders (DBD) at CDC has evolved from a patient-focused, services-supporting entity at inception, to one of the world leaders in the practice of public health to improve the lives of people at risk for or affected by nonmalignant blood disorders. The DBD’s earliest public health activities consisted of working with care providers in a network of hemophilia treatment centers to provide AIDS risk reduction services to people with hemophilia. Because this infectious disease threat has been reduced over time as a result of the developm...